Conference Call with Mankind Pharma Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Mankind Pharma announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from Operations at Rs 3,079 crore, up by 27% YoY Domestic revenue at Rs 2,544 crore, up 18% YoY, Exports at Rs 535 crore, up 100% YoY Adjusted EBITDA margin of 23.1% down by 120 bps YoY and PAT margin of 13.9% Diluted EPS of Rs 10.3 down by 12.5% YoY (FV Re.1) FY25 Financial Highlights: Revenue from Operations at Rs 12,207 crore, up by 19% YoY Domestic revenue at Rs 10,675 crore, up 13% YoY, Exports at Rs 1,532 crore, up 88% YoY Adjusted EBITDA margin of 25.9% up by 130 bps YoY and PAT margin of 16.4% Diluted EPS of Rs 49.1, up by 3% YoY (FV Re.1) Rajeev Juneja – Vice Chairman & Managing Director said, “Mankind’s revenue grew by 27% with adjusted EBITDA margins at ~23% in Q4 FY25 led by continued 1.3x outperformance in Chronic, strong growth in Consumer segment and BSV consolidation. In FY25, reported revenue growth was 19% with adj. EBITDA margin of ~26% This has been a transformative year at Mankind with several strategic initiatives to ensure higher productivity and outperform IPM as seen in the past. BSV integration is progressing well with key focus on R&D;, improving MR productivity & scaling mandate brands across domestic & International business. During FY25, we’ve laid a strong foundation to deliver long-term sustainable growth led by four key pillars - steady base business, fast growing specialty chronic, high potential OTC business, and high entry barrier super specialty portfolio of BSV.” Result PDF
Airlines company InterGlobe Aviation announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Capacity increased by 21.0% to Rs 42.1 billion Passengers increased by 19.6% to Rs 31.9 million Yield increased by 2.4% to Rs 5.32 and load factor improved by 1.1 pts to 87.4% Revenue from Operations increased by 24.3% to Rs 221,519 million Reduction in fuel CASK by 6.6% to Rs 1.60 EBITDAR of Rs 69,482 million (31.4% EBITDAR margin), compared to EBITDAR of Rs 44,123 million (24.8% EBITDAR margin) Net profit of Rs 30,675 million, compared to net profit of Rs 18,948 million FY25 Financial Highlights: Capacity increased by 13.1% to 157.5 billion Passengers increased by 11.1% to 118.6 million Yield increased by 1.3% to Rs 5.15 and load factor was 86.0% Revenue from Operations increased by 17.3% to Rs 808,029 million Reduction in fuel CASK by 3.1% to Rs 1.66 CASK ex fuel increased by 12.5% to Rs 3.00 EBITDAR of Rs 212,520 million (26.3% EBITDAR margin), compared to EBITDAR of Rs 175,447 million (25.5% EBITDAR margin) Excluding foreign exchange loss, profit amounted to Rs 88,676 million, compared to profit of Rs 88,897 million Net profit of Rs 72,584 million, compared to net profit of Rs 81,725 million Basic earnings per share of Rs 187.93 Pieter Elbers, CEO, said, “We are proud to report healthy financial performance for this quarter and the financial year 2025 as we reported a net profit of Rs 72,584 million. Our sustained performance is the result of record passenger volumes, operational efficiencies, agility and commitment demonstrated by IndiGo employees. A big thank you to our 118.6 million customers in FY25 for placing their trust in us and to all my IndiGo colleagues for their great work and relentless dedication. As we build on this momentum, we will continue to focus on cost leadership and further Internationalization with the start of our European operations. I am very pleased that the trust and continued support of our shareholders during the challenging covid period and beyond can now be rewarded with a recommended dividend of 10 rupees per share. Further, our continued performance and strong balance sheet has also been recognized by a leading International credit rating agency by assigning an Investment grade credit rating” Result PDF